Steven Adelman
Neurology · Des Moines, IANPI 1639283294
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $879 and has fallen 97.5% since, to $22 in 2024.
Across 56 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$215
- Biogen$188
- Supernus Pharmaceuticals, Inc.$96
- UCB, Inc.$81
- Teva Pharmaceuticals USA, Inc.$57
- AbbVie$57
- plus $399 from 15 others
What the payments were for
- Speaking & faculty fees$424%
- Food & beverage$1,05096%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $215 |
| Biogen | 3 | $188 |
| Supernus Pharmaceuticals, Inc. | 5 | $96 |
| UCB, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| AbbVie | 4 | $57 |
| Amgen | 3 | $55 |
| EMD Serono, Inc. | 2 | $43 |
| Acorda Therapeutics, Inc | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Eisai Inc. | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Pfizer | 2 | $25 |
| Genentech USA, Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Livanova USA, Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Promius Pharma LLC | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vumerity$110
How this compares
$1,092 in reported general payments places this provider in the 60th percentile of 132 neurology providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 33 | $1,338 |
| Levetiracetam | 26 | $163 |
| Topiramate | 26 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Upsher-smith Laboratories LLCTopiramate | $15 | $11326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 132 neurology providers in Iowa.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Mark PuricelliDes Moines$45K
- Keith KohoutDes Moines$36K
- Erik ArnesonDes Moines$10K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.